Open AccessIncobotulinumtoxinA (Xeomin)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.165
Subject(s) - sialorrhea , medicine , swallowing , surgery
CADTH recommends that Xeomin should be reimbursed by public drug plans for the treatment of chronic sialorrhea associated with neurological disorders if certain conditions are met.
Xeomin should only be covered to treat adult patients with moderate to severe chronic troublesome sialorrhea who do not have swallowing difficulties.
Xeomin should only be reimbursed if prescribed by a specialist with experience in managing neurological conditions, and the cost of Xeomin is reduced.